Provided by Tiger Fintech (Singapore) Pte. Ltd.

Summit Therapeutics PLC

24.11
+0.64502.75%
Post-market: 24.180.0700+0.29%19:59 EDT
Volume:13.10M
Turnover:326.02M
Market Cap:17.79B
PE:-77.77
High:26.97
Open:24.38
Low:23.04
Close:23.47
Loading ...

Summit Therapeutics Price Target Maintained With a $40.00/Share by JMP Securities

Dow Jones
·
Yesterday

Akeso survival data for ivonescimab misses expectations, STAT says

TipRanks
·
27 Apr

BUZZ-Summit Therapeutics closes 36% lower after interim data for cancer drug

Reuters
·
26 Apr

Summit Therapeutics Is Maintained at Buy by Jefferies

Dow Jones
·
26 Apr

Summit Therapeutics Gets Approval From China's Health Authority for Second Use of Ivonescimab

MT Newswires Live
·
26 Apr

Summit Therapeutics Shares Resume Trading After Halt, Last Down About 32% at Close to $25

THOMSON REUTERS
·
26 Apr

Summit Therapeutics trading resumes

TIPRANKS
·
26 Apr

Summit Therapeutics to resume trading at 3:20 pm ET

TIPRANKS
·
26 Apr

Summit Therapeutics says new ivonescimab data clinically meaningful

TIPRANKS
·
26 Apr

Wells says Summit, Akeso data ‘not the bull case,’ but not ‘bear case either’

TIPRANKS
·
26 Apr

Summit Therapeutics trading halted, news pending

TIPRANKS
·
26 Apr

Summit Therapeutics Inc : Jefferies Raises Target Price to $44 From $31

THOMSON REUTERS
·
25 Apr

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Business Wire
·
25 Apr

Evercore ISI Remains a Buy on Summit Therapeutics (SMMT)

TIPRANKS
·
24 Apr

Why Summit Therapeutics Inc. (SMMT) Went Up On Wednesday

Insider Monkey
·
24 Apr

Summit Therapeutics Says Phase 3 Cell Lung Cancer Trial Met Primary Endpoint; Shares Rise Pre-Bell

MT Newswires Live
·
23 Apr

BUZZ-Summit Therapeutics gains as lung cancer drug succeeds in second study in China

Reuters
·
23 Apr

S&P 500 Futures Rise In Premarket Trading; Pegasystems, Popular Inc. Lead

Dow Jones
·
23 Apr

Summit Therapeutics Rallies After Lung Cancer Drug Shows Positive Results

Dow Jones
·
23 Apr

Summit Therapeutics Shares up 11.4% Premarket After Co, Partner Akeso's Lung Cancer Treatment Meets Main Goal in Late Stage Trial Conducted in China

THOMSON REUTERS
·
23 Apr